Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOTRADECOL vs BYQLOVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and pediatric patients 1 year and older
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; prolonged in renal impairment.
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Primarily metabolized by CYP3A4 and CYP2D6.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Renal excretion of unchanged drug accounts for approximately 95% of elimination; fecal excretion is minimal (<5%).
>90% bound to plasma proteins, primarily albumin
Approximately 85% bound to serum albumin.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Volume of distribution is about 0.6 L/kg, indicating distribution into total body water.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
Oral bioavailability is approximately 80% (range 75–85%) under fasting conditions; food may reduce absorption.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
Contraindicated in patients with estimated creatinine clearance (Cr Cl) <30 m L/min. No dose adjustment required for Cr Cl ≥30 m L/min.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
Not recommended in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Safety and efficacy not established in pediatric patients (age <18 years).
For adolescents aged ≥12 years and weighing ≥35 kg, administer one tablet (50/200/25 mg) orally once daily. Safety and efficacy not established in pediatric patients <12 years or <35 kg.
No specific dose adjustment required; consider comorbidities and overall health status.
No specific dose adjustment recommended in elderly patients. Monitor renal function due to age-related decline.
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
No FDA boxed warning reported.
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Differentiation syndrome, which may be life-threatening or fatal; if suspected, initiate corticosteroids and hemodynamic monitoring.,QTc interval prolongation; monitor electrolytes and electrocardiograms.,Embryo-fetal toxicity.
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
None reported.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and can increase drug levels, leading to toxicity. No other known food interactions. Take with or without food, but consistent timing and fat content is recommended to maintain stable exposure.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens in first trimester exposure. In animal studies, no evidence of teratogenicity at clinically relevant exposures. Human data: insufficient for risk assessment; case reports of NTDs with bictegravir insufficient to rule out. First trimester: potential for NTDs, avoid unless benefit outweighs risk. Second/third trimester: limited data, no specific fetal risks identified, but use alternative if possible.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
Breastfeeding not recommended during BYQLOVI therapy due to potential for HIV-1 transmission via breast milk and unknown effects in infants. Bictegravir excretion into human milk unknown; emtricitabine: M/P ratio ~0.6; tenofovir alafenamide: M/P ratio ~0.3 (tenofovir). Limited data: low levels may be excreted. HIV-positive mothers should not breastfeed to avoid transmission.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
No specific dosing adjustments recommended during pregnancy due to limited data. Pharmacokinetic studies in pregnancy are lacking. Bictegravir AUC may decrease in second and third trimester; clinical relevance unknown. Consider alternative antiretroviral regimens with established safety data in pregnancy (e.g., dolutegravir plus emtricitabine/tenofovir disoproxil fumarate).
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
BYQLOVI (bruton tyrosine kinase inhibitor) is indicated for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. Monitor for atrial fibrillation, hypertension, and bleeding risk. Administer with a full glass of water and do not crush or open capsules. Dose reduction may be needed with strong CYP3A4 inhibitors. Avoid concurrent use with warfarin or other anticoagulants if possible.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
Take exactly as prescribed, with a full glass of water.,Do not open, break, or chew the capsules; swallow whole.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while on this medication.,Report any signs of bleeding (e.g., unusual bruising, black stools) or irregular heartbeat immediately.,Avoid activities that may cause injury due to increased bleeding risk.,Use effective contraception during treatment and for at least 1 month after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOTRADECOL vs BYQLOVI, answered by our medical review team.
SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. BYQLOVI is a Topical Retinoid that works by BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOTRADECOL and BYQLOVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. The standard adult dose of BYQLOVI is: BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOTRADECOL and BYQLOVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. BYQLOVI is classified as Category C. BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.